FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308987260> ?p ?o ?g. }

• W4308987260 abstract "For the first-line treatment of KRAS mutant non-small cell lung cancer (NSCLC) patients, immunotherapy or platinum-based chemotherapy are the main treatment method. Here, we investigated the clinical efficacy and prognosis those two regimens as first-line treatment in real-world practice.KRAS mutant NSCLC patients received chemotherapy or immunotherapy as first-line treatment from September 2014 to March 2022 were enrolled. Clinical characteristics, treatment scheme, clinical curative effect and follow-up data of enrolled patients were collected for analysis.Fifty patients received immunotherapy and 115 patients received chemotherapy were enrolled. Patients who received immunotherapy (HR = 0.350, 95%CI 0.156-0.781, P = 0.010), or pemetrexed-based regimen (HR = 0.486, 95%CI 0.255-0.928, P = 0.029), or antiangiogenic therapy (HR = 0.355, 95%CI 0.159-0.790, P = 0.011) were at a low risk of disease progression. And patients received antiangiogenic therapy had lower risk of death than those not (HR = 0.333, 95%CI 0.120-0.926, P = 0.035). Subgroup analysis revealed the immunotherapy compared to chemotherapy alone had lower risk of disease progression (HR = 0.377, 95%CI 0.166-0.856, P = 0.020) in PD-L1 expression ≥1% subgroup. And in non-G12C KRAS subgroup, but not in G12C KRAS subgroup, patients who received antiangiogenic therapy had lower risk of disease progression (HR = 0.254, 95%CI 0.098-0.656, P = 0.005) and death than those not (HR = 0.197, 95%CI 0.056-0.692, P = 0.011). In terms of different chemotherapy regimen, platinum-paclitaxel combined with antiangiogenic therapy achieved the highest ORR and DCR (P < 0.05), while the platinum-pemetrexed combined with antiangiogenic therapy had the longest PFS and OS (P < 0.001).For the first-line treatment of KRAS mutant NSCLC patients, immunotherapy, antiangiogenic therapy, and pemetrexed-based regimen could obtain more benefits. Subgroup analysis revealed the benefits of immunotherapy compared to chemotherapy were applicable in PD-L1 expression≥1% subgroup, and antiangiogenic therapy could benefit non-G12C KRAS subgroup, but not G12C KRAS subgroup. In terms of different chemotherapy regimen, platinum-pemetrexed combined with antiangiogenic therapy may be the preferred chemotherapy regimen." @default.
• W4308987260 created "2022-11-20" @default.
• W4308987260 creator A5006025957 @default.
• W4308987260 creator A5008115520 @default.
• W4308987260 creator A5018863416 @default.
• W4308987260 creator A5037538319 @default.
• W4308987260 creator A5046710897 @default.
• W4308987260 creator A5054655736 @default.
• W4308987260 creator A5059109729 @default.
• W4308987260 date "2022-11-14" @default.
• W4308987260 modified "2023-10-18" @default.
• W4308987260 title "A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice" @default.
• W4308987260 cites W2013312964 @default.
• W4308987260 cites W2025508342 @default.
• W4308987260 cites W2029908992 @default.
• W4308987260 cites W2032263978 @default.
• W4308987260 cites W2049553585 @default.
• W4308987260 cites W2050676588 @default.
• W4308987260 cites W2104347254 @default.
• W4308987260 cites W2122319990 @default.
• W4308987260 cites W2124427232 @default.
• W4308987260 cites W2145411470 @default.
• W4308987260 cites W2166923287 @default.
• W4308987260 cites W2174221502 @default.
• W4308987260 cites W2181288074 @default.
• W4308987260 cites W2219662516 @default.
• W4308987260 cites W2280154361 @default.
• W4308987260 cites W2294356527 @default.
• W4308987260 cites W2340056105 @default.
• W4308987260 cites W2345664439 @default.
• W4308987260 cites W2527905628 @default.
• W4308987260 cites W2560367415 @default.
• W4308987260 cites W2561459036 @default.
• W4308987260 cites W2567564314 @default.
• W4308987260 cites W2572174216 @default.
• W4308987260 cites W2586439898 @default.
• W4308987260 cites W2603411876 @default.
• W4308987260 cites W2767162493 @default.
• W4308987260 cites W2795913084 @default.
• W4308987260 cites W2796582438 @default.
• W4308987260 cites W2804812017 @default.
• W4308987260 cites W2805354595 @default.
• W4308987260 cites W2807361407 @default.
• W4308987260 cites W2888630309 @default.
• W4308987260 cites W2911842472 @default.
• W4308987260 cites W2911916015 @default.
• W4308987260 cites W2942446777 @default.
• W4308987260 cites W2944810278 @default.
• W4308987260 cites W2981114563 @default.
• W4308987260 cites W2995281612 @default.
• W4308987260 cites W2996463763 @default.
• W4308987260 cites W2998386687 @default.
• W4308987260 cites W3014882016 @default.
• W4308987260 cites W3036720502 @default.
• W4308987260 cites W3042326408 @default.
• W4308987260 cites W3128646645 @default.
• W4308987260 cites W3157248895 @default.
• W4308987260 cites W3172081492 @default.
• W4308987260 cites W4213085451 @default.
• W4308987260 cites W4281650778 @default.
• W4308987260 doi "https://doi.org/10.1186/s12885-022-10236-9" @default.
• W4308987260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36376839" @default.
• W4308987260 hasPublicationYear "2022" @default.
• W4308987260 type Work @default.
• W4308987260 citedByCount "0" @default.
• W4308987260 crossrefType "journal-article" @default.
• W4308987260 hasAuthorship W4308987260A5006025957 @default.
• W4308987260 hasAuthorship W4308987260A5008115520 @default.
• W4308987260 hasAuthorship W4308987260A5018863416 @default.
• W4308987260 hasAuthorship W4308987260A5037538319 @default.
• W4308987260 hasAuthorship W4308987260A5046710897 @default.
• W4308987260 hasAuthorship W4308987260A5054655736 @default.
• W4308987260 hasAuthorship W4308987260A5059109729 @default.
• W4308987260 hasBestOaLocation W43089872601 @default.
• W4308987260 hasConcept C121608353 @default.
• W4308987260 hasConcept C126322002 @default.
• W4308987260 hasConcept C143998085 @default.
• W4308987260 hasConcept C187960798 @default.
• W4308987260 hasConcept C2776256026 @default.
• W4308987260 hasConcept C2776694085 @default.
• W4308987260 hasConcept C2777701055 @default.
• W4308987260 hasConcept C2780140570 @default.
• W4308987260 hasConcept C2781187634 @default.
• W4308987260 hasConcept C2781413609 @default.
• W4308987260 hasConcept C44249647 @default.
• W4308987260 hasConcept C526805850 @default.
• W4308987260 hasConcept C535046627 @default.
• W4308987260 hasConcept C71924100 @default.
• W4308987260 hasConceptScore W4308987260C121608353 @default.
• W4308987260 hasConceptScore W4308987260C126322002 @default.
• W4308987260 hasConceptScore W4308987260C143998085 @default.
• W4308987260 hasConceptScore W4308987260C187960798 @default.
• W4308987260 hasConceptScore W4308987260C2776256026 @default.
• W4308987260 hasConceptScore W4308987260C2776694085 @default.
• W4308987260 hasConceptScore W4308987260C2777701055 @default.
• W4308987260 hasConceptScore W4308987260C2780140570 @default.
• W4308987260 hasConceptScore W4308987260C2781187634 @default.
• W4308987260 hasConceptScore W4308987260C2781413609 @default.
• W4308987260 hasConceptScore W4308987260C44249647 @default.
• W4308987260 hasConceptScore W4308987260C526805850 @default.

• next